Weight-loss drug trial reports kids given ingredient in Wegovy no longer obese
Novo Nordisk said on Monday that in a late-stage trial, 40.4 per cent of children aged 6 to under 12 treated with semaglutide, the active ingredient in its blockbuster weight-loss drug Wegovy, were no longer classified as having obesity after 68 weeks, assuming full adherence to the treatment.













